Mental health care for all

Our digital therapeutics are safe and effective non-drug options for mental health.*

Image of a woman confidently looking off into the distance, away from the camera
webp png replacement

Most people in need of mental health care don’t receive it

For those who are able to get care, 82% are given medication – but medication isn’t always the best option.1


of people experience moderately severe side effects.2


remission rate for the most common medications.3,4


of people prefer a non-drug option.5

Our digital therapeutics deliver effective help with no serious side effects

Daylight and Sleepio are easily accessible, safe, and highly effective.6,7

Trusted by the world’s leading organizations

For nearly a decade, we’ve been empowering employers and health plans
to help millions back to good mental health.

Simple to adopt,
low-lift engagement

Medication assessment program from Big Health is the easiest way to offer non-drug options to members or your population in need.

An abstract image depicting the Big Health logo being "selected" inside of a checked box.

Add coverage to your
pharmacy plan

Pre-approved by major pharmacy benefit managers, add coverage in as few as 10 days.

An abstract illustration of providing Big Health's digital therapeutics in the health care patient journey.

Offer access via
existing care pathways

Easily reach members at the time of need.

An abstract illustration depicting a Big Health invoice alongside other health care invoices. Billing is available via your company's Pharmacy Benefit Manager.

Bill via pharmacy invoice

Deep integrations mean you get to bill for therapeutic use via your pharmacy invoice.

We believe evidence
is a duty, not a chore

We’re committed to gold-standard clinical evidence. We have over 70 peer-reviewed publications with more than 28,000 participants, including more than 13 randomized controlled trials (RCTs).

Daylight logo


of patients achieved clinical improvement in anxiety.6

Sleepio logo


of patients achieved clinical improvement in insomnia.7

*Disclaimer: In accordance with FDA’s Current Enforcement Discretion Policy for Digital Health Devices for Psychiatric Disorders, for patients aged 18 years and older, who are followed by and diagnosed with Insomnia Disorder or Generalized Anxiety Disorder by a medical provider, Sleepio and Daylight can be made available as an adjunct to their usual medical care for Insomnia Disorder or Generalized Anxiety Disorder, respectively. Sleepio and Daylight do not replace the care of a medical provider or the patient’s medication. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for these indications. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

1. Terlizzi, E. P., & Zablotsky, B. (2020). Mental Health Treatment Among Adults: United States, 2019. NCHS Data Brief, (380), 1-8. 
2. Demyttenaere, K., Albert, A., Mesters, P., Dewè, W., De Bruyckere, K., & Sangeleer, M. (2005). What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?. Journal of Clinical Psychiatry66(7), 859-863.
3. Pillai, V., Roth, T., Roehrs, T., Moss, K., Peterson, E. L., & Drake, C. L. (2017). Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: an examination of response and remission rates. Sleep, 40(2), zsw044.
4. Rickels, K., & Rynn, M. (2002). Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry63, 9-16
5. McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. The Journal of clinical psychiatry, 74(6), 0-0.
6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168-1178.
7. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.